Literature DB >> 16458427

SRC-3/AIB1 protein and gene amplification levels in human esophageal squamous cell carcinomas.

Fang-Ping Xu1, Dan Xie, Jian-Ming Wen, Hui-Xi Wu, Yong-Dong Liu, Jiong Bi, Zhi-Li Lv, Yi-Xin Zeng, Xin-Yuan Guan.   

Abstract

It has been suggested that the steroid receptor coactivatior-3 (SRC-3) gene, also known as AIB1, ACTR, RAC3, p/CIP and TRAM-1, located at 20q12, plays an oncogenic role in several types of human cancers. In this study, we examined the encoded protein expression of SRC-3 and its copy number in 221 human esophageal squamous cell carcinomas (ESCCs). In this ESCC series, the overexpression and increased copy number of SRC-3 gene was detected in 46 and 13% of ESCCs, respectively. In addition, overexpression of SRC-3 was observed more frequently in primary ESCCs in late T stages (T3/T4) than that in earlier T1/T2 stages (P<0.05), but no significant association of expression of SRC-3 and status of lymph node metastases was observed (P>0.05). These results suggest that overexpression of SRC-3, caused by gene amplification/gain or other molecular mechanisms, might provide a selective advantage for the development and local invasion of certain subsets of ESCC. In addition, a significant correlation (P<0.05) of overexpression of SRC-3 with increased cell proliferation (through detection of Ki-67 expression) was observed in these ESCCs. These findings suggest a potential role of SRC-3 in the control of ESCC cell proliferation; such may be responsible, at least in part, for tumorigenesis and/or progression of ESCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458427     DOI: 10.1016/j.canlet.2005.12.030

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  27 in total

1.  Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques.

Authors:  Marilanda Ferreira Bellini; Ana Elizabete Silva; Marileila Varella-Garcia
Journal:  Genet Mol Biol       Date:  2010-06-01       Impact factor: 1.771

Review 2.  Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer.

Authors:  Robert G Maki
Journal:  J Clin Oncol       Date:  2010-10-25       Impact factor: 44.544

3.  AIB1 as an independent prognostic marker in hepatocellular carcinoma after hepatic resection.

Authors:  Jun-Min Song; Min Lu; Fang-Fang Liu; Xiao-Juan Du; Bao-Cai Xing
Journal:  J Gastrointest Surg       Date:  2011-11-04       Impact factor: 3.452

Review 4.  Nuclear receptor coactivators: structural and functional biochemistry.

Authors:  Yaroslava A Bulynko; Bert W O'Malley
Journal:  Biochemistry       Date:  2010-12-29       Impact factor: 3.162

5.  Chromosomal imbalances are uncommon in chagasic megaesophagus.

Authors:  Marilanda F Bellini; Antonio J Manzato; Ana E Silva; Marileila Varella-Garcia
Journal:  BMC Gastroenterol       Date:  2010-02-17       Impact factor: 3.067

Review 6.  Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family.

Authors:  Jianming Xu; Ray-Chang Wu; Bert W O'Malley
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

7.  Up-regulation of nuclear receptor coactivator amplified in breast cancer-1 in papillary thyroid carcinoma correlates with lymph node metastasis.

Authors:  M-Y Liu; H-P Guo; C-Q Hong; H-W Peng; X-H Yang; H Zhang
Journal:  Clin Transl Oncol       Date:  2013-04-20       Impact factor: 3.405

Review 8.  Nuclear receptor coregulators in cancer biology.

Authors:  Bert W O'Malley; Rakesh Kumar
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

9.  Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.

Authors:  Stephen A Boorjian; Hannelore V Heemers; Igor Frank; Sara A Farmer; Lucy J Schmidt; Thomas J Sebo; Donald J Tindall
Journal:  Endocr Relat Cancer       Date:  2008-10-09       Impact factor: 5.678

Review 10.  Steroid receptor coactivator-3 as a potential molecular target for cancer therapy.

Authors:  Jean Ching-Yi Tien; Jianming Xu
Journal:  Expert Opin Ther Targets       Date:  2012-08-27       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.